Workflow
兰卫医学收盘上涨2.24%,最新市净率2.32,总市值38.33亿元

Group 1 - The core viewpoint of the news is that Lanwei Medical has experienced a decline in both revenue and net profit in the latest quarterly report, indicating potential challenges in its business performance [1] - As of March 31, 2025, the number of shareholders for Lanwei Medical is 24,149, a decrease of 562 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] - The company's main business includes providing third-party medical testing and pathological diagnosis services, as well as selling in vitro diagnostic products and offering technical support [1] Group 2 - In the latest quarterly report for Q1 2025, Lanwei Medical reported revenue of 351 million yuan, a year-on-year decrease of 19.60%, and a net profit of -8.08 million yuan, reflecting a year-on-year decline of 854.01% [1] - The gross profit margin for the company stands at 19.95% [1] - The current market valuation of Lanwei Medical is 3.833 billion yuan, with a price-to-earnings ratio (PE) of -32.32 and a price-to-book ratio of 2.32 [2]